Soligenix (SNGX) EBITDA (2010 - 2026)
Soligenix's (SNGX) quarterly EBITDA came in at -$2.9 million in Q1 2026, up 4.68% YoY from -$2.8 million in Q1 2025, and up 16.97% on a QoQ basis from -$3.5 million in Q4 2025.
Soligenix (SNGX) EBITDA (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of EBITDA data on file, last reported at -$2.9 million in Q1 2026.
- Quarterly EBITDA rose 4.68% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.7 million (down 13.09% YoY) and the FY2025 annual result came in at -$11.8 million, down 25.49% from the prior year.
- EBITDA improved to -$2.9 million in Q1 2026, from -$3.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$1.6 million in Q2 2023 to a low of -$4.2 million in Q1 2022.
- A 5-year average of -$2.7 million and a median of -$2.8 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 87.7% — and 2023, when it surged 51.98%.
- Tracing SNGX's EBITDA over 5 years: stood at -$3.6 million in 2022, then soared by 40.12% to -$2.1 million in 2023, then plunged by 73.65% to -$3.7 million in 2024, then increased by 6.41% to -$3.5 million in 2025, then gained by 16.97% to -$2.9 million in 2026.
- The last three EBITDA figures came in at -$2.9 million (Q1 2026), -$3.5 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Soligenix | 6.06 Mn | 6.06 Mn | - | -2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.10 Mn |
| Mar 31, 2026 | -2.88 Mn |
| Dec 31, 2025 | -3.47 Mn |
| Sep 30, 2025 | -2.58 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Mar 31, 2025 | -3.03 Mn |
| Dec 31, 2024 | -3.71 Mn |
| Sep 30, 2024 | -1.87 Mn |
| Jun 30, 2024 | -1.74 Mn |
| Mar 31, 2024 | -2.12 Mn |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -1.63 Mn |
| Mar 31, 2023 | -2.15 Mn |
| Dec 31, 2022 | -3.57 Mn |
| Sep 30, 2022 | -3.08 Mn |
| Jun 30, 2022 | -3.40 Mn |
| Mar 31, 2022 | -4.19 Mn |
| Dec 31, 2021 | -4.51 Mn |
| Sep 30, 2021 | -3.36 Mn |